I am a graduate of Business Administration and have created my own Pharmaceutical website "BiotechPicklist.com". I have been investing and writing about biotechnology stocks for 5 years now and have extensive experience writing about the science and companies themselves. I am a Seeking ...
more I am a graduate of Business Administration and have created my own Pharmaceutical website "BiotechPicklist.com". I have been investing and writing about biotechnology stocks for 5 years now and have extensive experience writing about the science and companies themselves. I am a Seeking Alpha Contributor, and TalkMarkets Contributor as well. I Look for Pharmaceutical companies that are bringing new science to life that will be able to treat a variety of today's diseases and in which patients don't have many options. I look for the innovation of new drug compounds.
less
Latest Comments
A Solid Week In A Rocky Month
I agree this week has been a better week in itself. Also The ebola headline on Thursday has slight effect on bringing down the DOW at the end by 100 points but the DOW still closed up positive for the day. Even today on Friday the DOW went up despite the new case of ebola. Eventually these risk headlines have less and less negative effect after being known for so long.
Bill Ackman's Big Pharma Trade: The Drama Doesn't Stop
Yes I think it is insider trading. I mean you first set yourself up with a nice size stake in a company then wait a year or however many years and take it out. The problem with this is that you would be considered an insider because you place a huge stake and you know that you are going to buy it out. Just not plausible in the eyes of the law.
And The NYSE Breaks...
Well that can't be good! I don't think this comes as a surprise considering even the NASDAQ had a few problems with IPO's and other outages.
Carl Icahn Thinks Apple Stock Is Worth $203. Here’s Why He’s Wrong.
Well I agree with you. Here's why I think he's wrong as well Apple just refreshes Iphone products and hasn't created anything new. The rest of Apple's life will be refreshing Iphones and Ipads. Toda's earnings report though positive didn't even budge the share price of Apple as I see investors believe that Apple's sales are already baked into the share price.
“New Frontier Stocks” At Play In The Battle Against Ebola
Inovio Pharmaceuticals (INO) and Tekmira Pharmaceuticals (TKMR) both IMO have a bright future regardless of Ebola treatments. Although short term Tekmira will trade based off its ebola drug TKM-EBola and traders should be cautious if something goes wrong. But for Tekmira Investors regardless the company has an amazing future with its LNP technology platform.
Ebola Vs. Us
I would like to think that Tekmira is in good shape because it uses lipid nanoparticle delivery -- LNP. LNP is already being used by Alnylam for TTR-mediated Amyloidosis = rare disease in patients. So Tekmira using RNAi (RNA interference) may have the upper hand. But I also like Inovio's tech and Sarepta's tech.
Ebola Vs. Us
Wow just announced after hours first Ebola Case in U.S. Confirmed. Tekmira (TKMR), NewLink Genetics(NLNK), and Sarepta Therapeutics (SRPT) are all up after hours on this news. Tekmira itself is up 20% as of this comment writing, things may get worse before they get better. Ebola needs to be dealt with!
Rexahn Pharmaceuticals Looks To Find A New Partner Once Again For Cancer Compound
Sarepta Tumbles On New Drug Data But Presents A Big Buying Opportunity
Sarepta Tumbles On New Drug Data But Presents A Big Buying Opportunity